Mindera wins Prestigious Terra2 Skin Health Innovations Competition at 2021 Winter Clinical Dermatology Conference

SAN DIEGO, CA – Mindera Corporation announced that it has won the prestigious Terra2 Skin Health Innovations Competition at the 2021 Winter Clinical Dermatology Conference.  The Winter Clinical Dermatology Conference is an annual conference for dermatologists and dermatology residents to further education and discuss breakthrough innovations in their specialty.

Tobin Dickerson, Ph.D., Chief Scientific Officer and Co-founder of Mindera, presented Mind.Px, a Precision Medicine test to predict a patient’s personalized response to psoriasis biologics.  Led by a panel of leading experts, an audience of hundreds of dermatologists voted for Mindera in recognition of its revolutionary technology and implications on everyday clinical practice.  “We are honored to be selected as the winner of the Terra2 Skin Health Innovations Competition.  The recognition is rewarding for our entire team, and is a testament to the hard work that has been put into making Mind.Px a reality.  We eagerly look forward to bringing Mind.Px to the market later this year.”

Using Mindera’s proprietary FDA Registered dermal biomarker patch, the Mindera platform allows for minimally invasive extraction of rich biomarker data from individual patient skin. Captured molecules are sent to the Mindera CLIA-certified lab for analysis. Using Machine Learning, these baseline biomarkers can be correlated to clinical outcomes data from psoriasis patients who received specific biologic drugs, resulting in continuous evolving and improving predictive analyses for personalized drug responses. Systemwide, predicting biologic responses using Mind.Px can result in both improved psoriasis patient outcomes and billions of dollars of annual cost avoidance to the healthcare system.

About Mindera:

Mindera is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level.  Using a proprietary dermal biomarker patch, Next-Generation Sequencing (NGS) and Machine Learning, Mindera technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes.  Mindera is a CLIA certified Laboratory.  Find out more at www.minderahealth.com.

Featured Articles

Mindera’s SkinAtlas is a scalable platform that leverages artificial intelligence and machine learning to analyze patient-specific data collected from a dermal biomarker patch.


Mindera Newsletter

Stay ahead in the world of psoriasis treatment!

Subscribe to our newsletter and stay updated on the latest breakthroughs in biologic treatments.